HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yamada, J. Articles by Streilein, J. W. Search for Related Content PubMed PubMed Citation Articles by Yamada, J. Articles by Streilein, J. W.

Cytotoxic T Cells Play No Essential Role in Acute Rejection of Orthotopic Corneal Allografts in Mice

From the Schepens Eye Research Institute and the Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
PURPOSE. To determine whether cytotoxic T cells of the direct alloreactive type are activated and responsible for early, acute failure of orthotopic corneal allografts observed in eyes of C57BL/6 but not of BALB/c mice.

METHODS. Corneas from BALB/c and BALB.B mice were placed orthotopically in eyes of C57BL/6 and ß-2 microglobulin knockout mice (deficient in CD8⁺ cytotoxic T cells). Graft fates were assessed clinically, and the T lymphocytes of recipients were assayed for the capacity to lyse target cells bearing donor major (MHC) and/or minor histocompatibility (minor H) antigens (direct and indirect pathways, respectively).

RESULTS. Similar to BALB/c recipients, C57BL/6 mice with rejected cornea allografts acquired donor minor H–specific T cells. Unlike BALB/c recipients, C57BL/6 mice—both rejectors and acceptors—acquired donor MHC-specific T cells. ß-2 Microglobulin knockout mice showed rejection of corneal allografts in a manner indistinguishable from C57BL/6 mice, including early, acute rejection, yet T cells from ß-2 microglobulin knockout recipients of corneal allografts displayed no cytotoxic T cells specific for either donor MHC or minor H alloantigens.

CONCLUSIONS. Although C57BL/6 mice acquired donor MHC-specific cytotoxic T cells (direct alloreactive cells), neither these cells nor donor minor H–specific cytotoxic T cells (indirect alloreactive cells) play any essential role in corneal allograft rejection, including the early acute failure uniquely observed in C57BL/6 eyes.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Unlike other types of solid tissue grafts, allografts of cornea placed orthotopically in the eyes of experimental animals often experience extended, sometimes even indefinite, survival.^{1 2} Similarly, allografts placed in uncomplicated human eyes have a very high rate of success, even though only modest topical immunosuppression is typically used.^{3 4 5} In many instances in which the cornea graft confronts the host with numerous strong transplantation antigens, the earliest signs of rejection may not appear until 3 to 5 weeks after engraftment, whereas other types of solid tissue allografts usually undergo acute rejection within 1 to 3 weeks. Based on these types of observations, orthotopic corneal allografts placed in eyes of experimental animals and humans are believed to experience immune privilege.^{5 6 7} Despite the advantage displayed by orthotopic corneal allografts compared with other types of grafts, rejection of orthotopic corneal allografts in humans still represents a significant clinical problem. More corneal transplantations are performed per year (>50,000) in the United States and Eastern Europe than any other type of transplantation, and a success rate of 90%⁴ means that more than 5,000 grafts fail per year. In addition, cornea allografts placed in so-called high-risk eyes experience an unacceptably high rate of rejection.^{8 9} In experimental animals, the tempo of rejection in high-risk eyes is very fast (measured in days),¹⁰ rivaling that of other solid tissue allografts. Therefore, understanding the pathogenesis of corneal allograft rejection has a high research and clinical priority.

In the recent past, using a model of orthotopic corneal transplantation in mice, we have analyzed the fate of grafts in eyes of BALB/c and C57BL/6 mice.^{11 12} In certain respects, the fate of the grafts and the immune responses of both types of recipients were similar. Thus, a significant number of allografts survived indefinitely in each, and the incidence of acceptance of major histocompatibility complex (MHC)–only disparate grafts was significantly higher than the incidence of acceptance of minor histocompatibility (minor-H)–only disparate grafts. All recipients of both strains acquired donor-specific delayed hypersensitivity (DH) within 4 weeks of engraftment, irrespective of whether the grafts were eventually rejected. Of particular interest is the finding that the systemic immunity (DH) displayed by graft recipients of both strains was directed at minor H–encoded, rather than MHC-encoded alloantigens. Moreover, all animals in which grafts were accepted for longer than 8 weeks (defined as indefinite survival) acquired donor-specific anterior chamber–associated immune deviation.^{2 11}

Despite these similarities, the fates of grafts in eyes of BALB/c and C57BL/6 mice were not identical. First, the incidence of rejection was considerably higher in C57BL/6 than in BALB/c mice. Second, a large proportion of grafts in eyes of C57BL/6 recipients displayed early acute rejection (within 2–3 weeks), whereas rejections of cornea grafts during this early period after grafting occurred very infrequently in BALB/c eyes. Third, in BALB/c rejector mice the ability to display donor-specific DH was first gained, then lost, whereas once the cornea grafts were rejected in C57BL/6 mice, a high level of donor-specific DH was retained indefinitely.¹¹

Recently, we analyzed the donor-specific cytotoxic T-cell responses of BALB/c mice to orthotopic corneal allografts. These experiments revealed that mice with rejected grafts (but not mice with accepted grafts) acquired primed minor-H–specific T cells. However, none of the mice displayed cytotoxicity directed at target cells bearing donor MHC alloantigens.¹³ Thus, in BALB/c mice, direct alloreactive T cells (either CD4⁺ or CD8⁺) specific for donor MHC alloantigens are not activated. Instead, donor minor-H–specific DH and T cells are readily detectable, especially in mice in which grafts are rejected. Combined with evidence that sensitization of cornea allograft recipients to donor alloantigens correlates temporally with infiltration of recipient Langerhans’ cells into the graft,¹⁴ we have deduced that only the so-called indirect pathway of allorecognition is activated by orthotopic corneal allografts.

Because rejection of orthotopic corneal allografts in C57BL/6 recipients is more rapid and of higher frequency than in BALB/c recipients, we hypothesized that early acute rejection in C57BL/6 mice is caused by the acquisition of direct (MHC-specific) alloreactive T cells. To test this hypothesis, we examined whether primed direct and/or indirect alloreactive T cells are generated in C57BL/6 recipients of allogeneic cornea grafts. Our results indicate that C57BL/6 recipients resemble BALB/c recipients, in that rejectors acquired donor minor H–specific T cells. Unlike BALB/c mice, C57BL/6 recipients of BALB/c cornea grafts also acquired direct, donor MHC-specific T cells. However, this was equally true in mice in which grafts were or were not rejected. Finally, corneal allografts placed in eyes of ß2-microglobulin–deficient mice (that are deficient in CD8⁺ T cells) displayed the same high incidence and rate of rejection, including early acute graft failure, that is found when wild-type C57BL/6 mice receive orthotopic corneal allografts. Thus, although corneal allografts in C57BL/6 eyes can invoke direct alloreactive T cells, these cells are not required for the vigorous immune rejections observed in this strain of mice.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Mice
Adult male BALB/c (H-2^d) and C57BL/6 (H-2^b) were purchased from Taconic Farms (Germantown, NY). Adult male BALB.B (C.B10-H2^b/LilMcdJ, H-2^b), and ß2-microglobulin–deficient (C57BL/6J-B2m^tm1Unc, H-2^b), referred to as ß2µ KO mice in this article, were purchased from Jackson Laboratory (Bar Harbor, ME)¹⁵ between 8 and 12 weeks of age and used as experimental subjects. All animals were treated according to the Association for Research in Vision and Ophthalmology Statement for the use of Animals in Ophthalmic and Vision Research.

Induction of Corneal Neovascularization
Intrastromal sutures induce robust neovascularization of the normally avascular corneal stroma,¹⁶ and untreated allografts placed in these high-risk eyes are rejected swiftly, as previously described.¹⁰ Briefly, three interrupted 11-0 sutures were placed in the central cornea of one eye of a normal recipient mouse on day -14 under aseptic microsurgical technique using an operating microscope. The neovascularized corneas then served as high-risk beds for orthotopic corneal transplants on day 0. The sutures used to induce neovascularization were removed at the time of transplantation.

Orthotopic Corneal Transplantation
The usual method for corneal transplantation has been described in detail elsewhere.^{11 12} Briefly, each recipient was deeply anesthetized with an intraperitoneal injection of 3 mg ketamine and 0.0075 mg xylazine before all surgical procedures. The central 2-mm of the donor cornea was excised and secured in recipient graft beds with eight interrupted 11-0 nylon sutures (Sharppoint; Vanguard, Houston, TX). Antibiotic ointment was applied to the corneal surface, and the lids were closed for 24 hours by tarsorrhaphy (8-0 nylon sutures). All grafted eyes were examined after 72 hours; grafts with technical difficulties (hyphema, infection, or loss of anterior chamber) were excluded from further consideration. Transplantation sutures were removed in all cases on day 7.

Assessment of Graft Survival
Grants were evaluated by slit lamp biomicroscopy twice a week. At each time point grafts were scored for opacification between 0 and 5+: 0, clear and compact graft; 1+, minimal superficial opacity; 2+, mild deep (stromal) opacity with pupil margin and iris vessels (iris structure) visible; 3+, moderate stromal opacity with only the pupil margin visible; 4+, intense stromal opacity with the anterior chamber visible; 5+, maximal corneal opacity with total obscuration of the anterior chamber. Early acute rejection was diagnosed if grafts received a clinical score of 3+ or more at 2 weeks. Grafts were also judged to be rejected if a score of 2+ or more was achieved at any time thereafter, and this score was maintained through the 8-week observation interval. Corneal grafts that undergo transient opacification followed by clearing are not considered rejected.¹²

Restimulation of Cytotoxic T Cells In Vitro
To determine whether alloantigens expressed on donor cornea grafts lead to priming of specific T cells, four or more recipients in each group were killed at 4 weeks after grafting and the ipsilateral cervical lymph nodes and spleens removed. Potential effector cells from recipients (5 x 10⁶) and irradiated (2000 R) stimulator lymphoid cells from appropriate donors (5 x 10⁶) were plated together in 24-well plates in 2 ml of culture medium containing RPMI 1640 (Gibco, Grand Island, NY) with the following additives: 10% heat-inactivated fetal bovine serum (Hyclone, Logan, UT), 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 2 mM L-glutamine, and 100 U and 100 µg/ml penicillin and streptomycin, respectively (Gibco), 5 mM HEPES (Gibco), and 2 x 10^-5 M 2-mercaptoethanol. Cells were cultured at 37°C in a humidified 5% CO₂ atmosphere for either 3 days (to assay primed, direct, MHC-specific cytotoxicity) or 6 days (to assay primed, indirect, minor H–specific cytotoxicity). When cultured for 6 days, 1 ml of medium was removed from the culture and 1 ml of fresh medium was added on day 3.

Cytotoxicity Assay
To assess direct, MHC-specific cytotoxicity, ⁵¹chromium (Cr)-release assays were performed on day 3 after restimulation in vitro. P815 cells,¹⁷ tumor cells derived from DBA/2 mice, which share the H-2^d alleles of BALB/c, served as targets. To assess indirect, minor H–specific cytotoxicity, ⁵¹Cr-release assays were performed on day 6 after restimulation in vitro. Spleen cells from BALB.B donors (share H-2^b allele with C57BL/6, but display multiple minor H antigenic disparities) were placed in 10 ml culture medium for 3 days before assay in the presence of 5 µg/ml concanavalin A (ConA). On the day of assay, ConA-target cells were labeled with ⁵¹Cr and mixed (1 x 10⁴ target cells) with effector cells in triplicate at ratios of 6:1, 12:1, 25:1, 50:1, and 100:1. Some experiments described in Table 1 have a maximum E:T ratio of 75:1. Six wells containing only medium and target cells were used to measure spontaneous release, and six wells containing 5 N HCl and target cells were used to measure maximal radioisotope release. After 4 hours’ incubation at 37°C in 5% CO₂, 25 µl of culture supernatant was removed from each well, and radioactivity was measured. Specific lysis was determined according to the formula: percentage of specific lysis = (cpm mean experimental - cpm mean spontaneous release)/(cpm mean maximal release - cpm mean spontaneous release) x 100. Spontaneous release ranged between 5% and 15%. All experiments were repeated at least three times with similar results, and the results of representative experiments are presented in the figures. For each data point shown in the figures, lymph nodes, or spleens were harvested and pooled from at least three mice.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
Acquisition of Indirect Minor H–Specific Cytotoxic T Cells by C57BL/6 Recipients of Orthotopic Corneal Allografts
Panels of C57BL/6 mice underwent orthotopic transplantation of corneas obtained from eyes of either BALB/c (MHC plus minor H disparate), or BALB.B (minor H–only disparate) donors. After 4 weeks, cervical lymph nodes ipsilateral to the graft-containing eye and spleens were harvested. For positive control animals, panels of C57BL/6 mice received a subcutaneous (SC) injection of 10 x 10⁶ BALB/c or BALB.B lymphoid cells 2 weeks before death. Putative effector cells (5 x 10⁶) were cultured for 6 days in the presence of x-irradiated (2000 R) lymphoid cells from BALB.B donors. At the end of the culture interval, the cells were harvested and assayed for cytotoxic activity directed at ⁵¹Cr-labeled BALB.B lymphoid cells that had been stimulated in vitro with ConA. The results of a representative experiment are presented in Table 1 . In vitro stimulated lymphocytes from lymph nodes of C57BL/6 mice that rejected BALB/c cornea grafts (MHC plus minor H disparate) displayed a high level of target cell lysis (comparable to positive control animals), whereas similar lymphocytes from mice with healthy cornea grafts displayed insignificant levels of cytolysis. In the same manner, in vitro-stimulated lymphocytes from C57BL/6 mice that rejected BALB.B corneas (minor H-only disparate) lysed BALB.B target cells (comparable to positive control animals), although lymphocytes from mice with accepted grafts were incapable of lysing BALB.B. Similar findings emerged from studies in which recipient spleen cells were used (data not shown). These results indicate that C57BL/6 mice that reject orthotopic corneal allografts acquire T cells that are minor H–specific and therefore have been activated through the indirect pathway of allorecognition. A similar T-cell response has been reported for BALB/c mice bearing orthotopic corneal allografts.

Acquisition of Direct, MHC-Specific Cytotoxic T Cells by C57BL/6 Recipients of Orthotopic Corneal Allografts
C57BL/6 mice underwent orthotopic transplantation of corneas obtained from BALB/c donors. At 4 weeks, ipsilateral cervical lymph nodes, as well as spleens, were harvested and stimulated in vitro for 3 days with x-irradiated BALB/c lymphoid cells. Positive control animals were immunized SC with BALB/c lymphoid cells 2 weeks before in vitro stimulation. The cultured cells were then harvested and assayed for cytotoxic activity against ⁵¹Cr-labeled P815 cells (a mast cell tumor derived from DBA/2 mice, expressing H-2^d alloantigens identical with BALB/c). The results of a representative experiment are presented in Table 1 . As anticipated, in vitro stimulated lymphoid cells from positive control mice caused significant release of radioisotope from P815 target cells. Similarly, in vitro stimulated lymphoid cells from C57BL/6 mice in which BALB/c grafts were rejected also lysed P815 target cells. In an unexpected finding, in vitro stimulated lymphoid cells from C57BL/6 mice bearing healthy (accepted) BALB/c grafts caused lysis of P815 targets. Results of a similar nature were obtained with spleen cells from C57BL/6 recipients of orthotopic corneal allografts. These findings indicate that the direct pathway of allorecognition is open in C57BL/6 mice receiving orthotopic grafts of allogeneic corneas. Although direct T cells were detectable in both rejector and acceptor mice, these results encouraged us to determine whether direct alloreactive T cells might be important or required for early, acute rejection of BALB/c cornea grafts in eyes of C57BL/6 mice.

Fate of Orthotopic Corneal Allografts in Eyes of Mice Deficient in CD8⁺ T Cells
Mice with the gene for ß-2 microglobulin rendered dysfunctional (ß2µ KO) are deficient in CD8⁺ T cells, and their lymphoid cells are unable to lyse target cells in an antigenically specific manner. We turned to these mice as suitable subjects to test the hypothesis that CD8⁺ cytotoxic T cells are responsible for early, acute rejection of orthotopic corneal allografts in C57BL/6 mice. C57BL/6 and ß2µ KO mice received orthotopic corneal grafts from BALB/c donors. In one panel of mice, the grafts were placed in normal eyes. In another panel, the grafts were placed in eyes rendered high risk—that is, neovascularized secondary to sutures placed through the central cornea 2 weeks previously. As a negative control, syngeneic grafts were placed on normal eyes (n = 5). The fate of the grafts was assessed clinically, and the results are summarized in Figures 1A 1B and 1C . The evidence indicates that the tempo and incidence of rejection of BALB/c cornea grafts were highly similar in wild-type C57BL/6 (n = 30) and ß2µ KO mice (n = 11) and that significant numbers of grafts in both types of recipients were rejected early and acutely (Fig. 1A) . As revealed in Figure 1B , allografts in high-risk eyes were rejected in both wild-type (n = 10) and ß2µ KO mice (n = 12) in a comparably acute and vigorous fashion.

View larger version (20K): [in this window] [in a new window]   Figure 1. Fate of allogeneic corneas in eyes of mice deficient in CD8+ T cells. MHC plus minor H–disparate BALB/c corneas (A, B), or minor H–only disparate BALB.B corneas (C) were placed in normal (A, C) or high-risk (neovascularized corneas; B) eyes of C57BL/6 and ß2µ KO mice or syngeneic BALB/c mice. Cumulative graft survival (retention of corneal clarity) through 56 days is presented as Kaplan–Meier plot. Curves of C57BL/6 and ß2µ KO recipients were statistically indistinguishable from each other in any plot.

Search for Residual Cytotoxic T-Cell Activity in CD8⁺ T-Cell–Deficient Mice Bearing Orthotopic Corneal Allografts
The deficit of CD8⁺ T cells in ß2µ KO mice is not absolute.¹⁸ Therefore, it is possible that the conclusions drawn from the previous grafting experiments are not justified and that the small numbers of CD8⁺ T cells present in these mice are sufficient to cause rejection of orthotopic corneal allografts. To test this possibility, lymphoid cells were harvested from ß2µ KO mice 4 weeks after they received orthotopic corneal grafts from BALB/c donors. Other ß2µ KO mice, which were immunized SC with BALB/c lymphoid cells, served as conventionally primed control animals. Lymphoid cells were also harvested from naive C57BL/6 and ß2µ KO donors and from C57BL/6 mice immunized SC with BALB/c spleen cells 2 weeks previously. Suspensions of lymphoid cells were stimulated in vitro with x-irradiated cells from BALB/c donors for 3 days or from BALB.B donors for 6 days. The responding cells were then harvested and assayed on ⁵¹Cr-labeled cells appropriate to determine whether direct or indirect alloreactive T cells were present. The results of representative experiments are presented in Figure 2 . When BALB/c cells were used as stimulators and P815 cells were used as targets, T cells from SC primed C57BL/6 donors were cytotoxic (see Fig. 2A ). BALB/c-stimulated T cells from none of the other sources lysed P815 targets at a high level, although T cells from in vivo primed ß2µ KO donors appeared to cause minimal radioisotope release at the highest effector-to-target (E:T) cell ratios (100:1). When BALB.B donor cells were used to stimulate T cells from wild-type mice bearing BALB/c grafts or immunized with BALB/c lymphoid cells, only T cells from mice primed SC with lymphoid cells displayed any cytotoxicity directed at BALB.B ConA blast cells (see Fig. 2B ). Finally, when BALB.B donor cells were used to stimulate wild-type T cells from mice bearing BALB.B grafts (or that had been immunized SC with BALB.B lymphoid cells), SC-primed T cells were efficient killers of BALB.B target cells (see Fig. 2C ). Of the other cell sources, only a barely detectable increase in release of radioisotope was observed with T cells from ß2µ KO mice primed by SC injections of BALB.B lymphoid cells. It is important to point out that in none of these experiments did T cells harvested from ß2µ KO mice bearing orthotopic corneal allografts display any evidence of donor-specific cytotoxic activity. However, it is still possible that ß2µ KO mice may in some as yet undetermined way compensate for the absence of CD8⁺ T cells and therefore mask the role of CD8⁺ T cells in corneal allograft rejection. We conclude that corneal allografts fail to prime the few residual CD8⁺ T cells present in ß2µ KO mice, and that the ability of these mice to reject orthotopic corneal allografts in a manner indistinguishable from wild-type control animals is unrelated to CD8⁺ cytotoxic T cells.

View larger version (29K): [in this window] [in a new window]   Figure 2. Cytotoxic T-cell activity from CD8+ T-cell–deficient mice bearing orthotopic corneal allografts. MHC plus minor H–disparate BALB/c (A, B), or minor H–only disparate BALB.B (C) corneas were placed in eyes of C57BL/6 and ß2µ KO recipients. Positive control (primed) C57BL/6 and ß2µ KO mice were immunized SC with BALB/c (A, B) or BALB.B (C) spleen cells. Normal C57BL/6 and ß2µ KO mice served as negative control (naive). Four weeks (graft recipients) or 2 weeks (positive control animals) later, when the fate of the grafts was known, ipsilateral/draining cervical lymph node cells were stimulated in vitro for 3 days (A) or 6 days (B, C) with x-irradiated BALB/c (A, B) or BALB.B (C) spleen cells, harvested, and assayed on 51Cr-labeled target cells: P815 cells of DBA/2 origin (A) or ConA-activated splenocytes of BALB.B origin (B, C). Mean (± SEM) percentage of specific radioisotope release in 4-hour triplicate assays at differing E:T ratios are presented (*P < 0.05).

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

The evidence presented in this report and previously²⁴ demonstrates, at least in a model using C57BL/6 and BALB/c mice, that CD8⁺ cytotoxic T cells play no essential role in acute or subacute rejection of orthotopic corneal grafts. The tempo and incidence of rejection of allogeneic corneas grafted to eyes of ß2µ KO mice were indistinguishable from that of similar grafts in eyes of wild-type C57BL/6 mice. Because our results reveal that orthotopic corneal allografts elicit no detectable T cells in ß2µ recipients, we conclude that neither early acute nor subacute cornea graft rejection involves T cells.

Recipients of solid tissue grafts can become sensitized through two distinctly different pathways of allorecognition. One set of alloreactive T cells (direct) recognizes donor MHC class I or II alloantigens directly (without benefit of processing by antigen-presenting cells [APCs]). Direct alloreactive T cells are capable on their own of rejecting solid tissue grafts, and rejection of this type is typically acute (within 1–2 weeks). Another set of alloreactive T cells (indirect) recognizes donor MHC as well as minor H alloantigens only after they have been taken up by recipient antigen presenting cells and presented by recipient MHC molecules. Depending on the number of MHC and minor H alloantigenic differences, indirect alloreactive T cells can mediate acute (many antigenic differences) as well as subacute (fewer antigenic differences) graft rejection. We have previously shown that orthotopic corneal allografts in BALB/c mouse eyes elicit sensitized CD4⁺ and CD8⁺ T cells of the indirect type only. Because corneal allografts in BALB/c mice are not typically rejected until 3 or more weeks after grafting and because a significant proportion of corneal allografts in eyes of C57BL/6 mice are rejected before 3 weeks, we hypothesized that direct T cells, specific for donor MHC alloantigens, mediate early, acute rejection in the latter mice.

Our results clearly indicate that C57BL/6 mice differ from BALB/c mice in their ability to acquire direct, donor MHC-specific T cells after receiving orthotopic corneal allografts. However, two pieces of data argue against these cells’ being responsible for early acute rejection in this instance. First, direct T cells were detected readily in both acceptor and rejector C57BL/6 mice. Second, no direct (or indirect) donor-specific T cells were detected in ß2µ KO mice, yet these mice also displayed the capacity to reject orthotopic corneal allografts in an early, acute fashion. Thus, our hypothesis is incorrect, and early acute rejection of cornea grafts by C57BL/6 mice, compared with BALB/c mice, is not due to activation of donor MHC-specific T cells of the direct type.

In one sense, this conclusion strengthens the thesis that acute rejection of orthotopic corneal allografts in mice is mediated solely by CD4⁺ T cells, presumably of the DH type. But in another sense, we are at a loss to explain the apparent irrelevancy of donor-specific T cells evoked by orthotopic cornea allografts. Donor-specific T cells of the direct type have only been detected in normal C57BL/6 recipients, not in normal BALB/c mice. However, in both BALB/c and C57BL/6 recipients of cornea grafts, donor minor H–specific T cells of the indirect type are easily detected. Moreover, in both strains, only mice that reject their orthotopic grafts acquire indirect T cells. T cells from mice that accept their cornea grafts display no evidence that minor H–specific indirect T cells are activated. The paradox is that there is a tight correlation between graft rejection and acquisition of indirect T cells, yet graft rejection proceeds normally in the complete absence of CD8⁺ T cells!

We were surprised that direct activation of CD8⁺ cytotoxic T cells occurred in C57BL/6 mice but not BALB/c mice. The absence of direct T cells in BALB/c mice in our previous experiments is more easily explained than the presence of these cells in the current series of experiments. The absence of direct CD8⁺ T cells in BALB/c mice is most likely due to the absence of donor-derived class I–positive APCs in the corneal allograft. These cells are believed to be responsible for activating direct CD8⁺ T cells. However, this suggests these APCs must be present in the donor corneas when direct CD8⁺ T cells are activated in the C57BL/6 recipients receiving BALB/c donors. There are at least two possible explanations for these data. First, there are some, as of yet undetermined, class I–positive APCs present in corneal tissue and either the frequency or immunogenicity of these allo-APCs are different in these two strains of mice. Second, direct CD8⁺ T cells are not activated by donor APCs, but through class I–positive donor corneal cells that migrate from the eye to the draining lymph node. The frequency of these cells migrating from the eye to the lymph node could be different in these two strains of mice. The latter possibility seems less likely, because there is little evidence that cells other than professional APCs can prime specific T cells. However, currently there are no data indicating APCs are present in the normal cornea.

In their report of 1991, He et al.²⁴ came to conclusions similar to ours, using anti-CD4 and anti-CD8 antibodies to demonstrate that CD4⁺, but not CD8⁺, T cells are required for rejection of orthotopic corneal grafts. At the time of their study, the question of relative contributions of direct and indirect pathways of allorecognition to rejection of orthotopic corneal allografts was not formally considered. Moreover, the strain combination they used—C57BL/6 corneas to BALB/c recipients—precluded an analysis of this issue. Our findings, using corneal allografts in eyes of C57BL/6 recipients, add at least two important new dimensions to our understanding of corneal allograft rejection. First, unlike BALB/c mice, C57BL/6 recipients of MHC-disparate orthotopic corneal allografts acquire direct alloreactive T cells, making it possible to test for the participation of these cells in graft rejection. Second, by using ß2µ KO mice (C57BL/6 background), we were able to exclude formally a role for T cells of either the direct or indirect type in acute rejection of orthotopic cornea grafts.

When allogeneic corneas are grafted into high-risk eyes of BALB/c and C57BL/6 mice, they are subjected to an early, vigorous alloimmune response. Most of these grafts are destroyed within 7 to 10 days. In both instances, the lymphoid organs of the recipients acquire donor MHC-specific T cells of the direct alloreactive type. Similarly, direct alloreactive T cells that mediate DH are also activated. Yet, corneas grafted into high-risk eyes of ß2µ KO mice showed the same high and rapid rate of rejection as did grafts in high-risk eyes of C57BL/6 mice. These results suggest that even the direct T cells activated by grafts in high-risk eyes are irrelevant to graft outcome. We conclude that whether corneas are grafted into normal eyes or into high-risk eyes, the rejections that are observed as early as 1 week after grafting or as late as 6 weeks after grafting are mediated solely by CD4⁺ T cells.

The dissociation between activated donor-specific T cells and the absence of a role for these cells in rejection of orthotopic corneal allografts can be at least partly explained. With respect to T cells of the indirect type (directed at peptides of minor H antigens displayed on recipient MHC class I molecules), in fully allogeneic corneas of the type used in our experiments (MHC mismatched), the cells of the graft are not capable of serving as targets, in that none express recipient MHC class I molecules. BALB/c grafts on C57BL/6 recipients represent this type of situation. However, when minor H–disparate donor and recipient share the same MHC, cells of graft can serve as targets of indirect T cells. BALB.B grafts on C57BL/6 recipients represent this type of situation. Regarding T cells of the direct type (directed a donor MHC class I antigens), parenchymal cells of the graft can express target class I molecules. Because graft epithelium is rapidly replaced after keratoplasty in mice (Hori J, unpublished observation, 1999), expression of MHC molecules by corneal epithelial cells may be irrelevant to graft outcome. The fate of the graft seems to be determined primarily by the fate of its endothelium, and it is relevant that constitutive expression of class I molecules on corneal endothelium is much lower than other types of cells,²⁹ rendering them relatively weak as targets of class I–specific T cells. Moreover, corneal endothelial cells constitutively express CD95 ligand (CD95L).³⁰ Perhaps when activated (CD95⁺), direct alloreactive T cells contact graft endothelium, interaction of CD95 with its ligand induces apoptosis of the T cells before they can deliver a lethal hit to the endothelium. The reports of Stuart et al.³¹ and Yamagami et al³² provide strong evidence that CD95L expression on corneal endothelium is important in protecting the graft against acute rejection.

	Footnotes

 
Supported in part by US Public Health Service Grants EY-10765 and EY-19765.

Submitted for publication August 2, 1999; revised December 22, 1999; accepted February 2, 2000.

Commercial relationships policy: N.

Corresponding author: J. Wayne Streilein, Schepens Eye Research Institute, 20 Staniford Street, Boston, MA 02114-2500. waynes{at}vision.eri.havard.edu

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. She, SC, Steahly, LP, Moticka, EJ (1990) A method for performing full-thickness, orthotopic, penetrating keratoplasty in the mouse Ophthalmic Surg 21,781-785[Medline][Order article via Infotrieve]
2. Sonoda, Y, Streilein, JW (1993) Impaired cell-mediated immunity in mice bearing healthy orthotopic corneal allografts J Immunol 150,1727-1734[Abstract]
3. Smith, RE, McDonald, HR, Nesburn, AB, Minckler, DS (1980) Penetrating keratoplasty: changing indications, 1947 to 1978 Arch Ophthalmol 98,1226-1229[Medline][Order article via Infotrieve]
4. . The Collaborative Corneal Transplantation Studies Research Group (1992) The collaborative corneal transplantation studies (CCTS): effectiveness of histocompatibility matching in high-risk corneal transplantation Arch Ophthalmol 110,1392-1403[Medline][Order article via Infotrieve]
5. Niederkorn, JY (1990) Immune privilege and immune regulation in the eye Adv Immunol 48,191-226[Medline][Order article via Infotrieve]
6. Streilein, JW (1995) Immunological non-responsiveness and acquisition of tolerance in relation to immune privilege in the eye Eye 9,236-240
7. Streilein, JW (1987) Immune regulation and the eye: a dangerous compromise FASEB J 1,199-208[Abstract]
8. Maguire, MG, Stark, WJ, Gottsch, JD, et al (1994) Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies Ophthalmology 101,1536-1547[Medline][Order article via Infotrieve]
9. Mader, TH, Stulting, RD (1991) The high-risk penetrating keratoplasty Ophthalmol Clin North Am 4,411-426
10. Sano, Y, Ksander, BR, Streilein, JW (1995) Fate of orthotopic corneal allografts in eyes that cannot support anterior chamber-associated immune deviation induction Invest Ophthalmol Vis Sci 36,2176-2185[Abstract/Free Full Text]
11. Yamada, J, Streilein, JW (1998) Fate of orthotopic corneal allografts in C57BL/6 mice Transplant Immunol 6,161-168[Medline][Order article via Infotrieve]
12. Sonoda, Y, Streilein, JW (1992) Orthotopic corneal transplantation in mice: evidence that the immunogenetic rules of rejection do not apply Transplantation 54,694-704[Medline][Order article via Infotrieve]
13. Sano, Y, Streilein, JW, Ksander, BR (1999) Detection of minor alloantigen specific cytotoxic T cells after rejection of murine orthotopic corneal allografts: evidence that graft antigens are recognized exclusively via the "indirect pathway" Transplantation 68,963-970[Medline][Order article via Infotrieve]
14. Sano, Y, Ksander, BR, Streilein, JW (2000) Langerhans cells, orthotopic corneal allografts, and direct and indirect pathways of T cell allorecognition Invest Ophthalmol Vis Sci 41,1422-1431[Abstract/Free Full Text]
15. Koller, BH, Marrack, P, Kappler, JW, Smithies, O. (1990) Normal development of mice deficient in beta 2M, MHC class I proteins, and CD8+ T cells Science 248,1227-1230[Abstract/Free Full Text]
16. Dana, MR, Streilein, JW (1996) Loss and restoration of immune privilege in eyes with corneal neovascularization Invest Ophthalmol Vis Sci 37,2485-2494[Abstract/Free Full Text]
17. Van Pel, A, De Plaen, E, Boon, T. (1985) Selection of highly transfectable variant from mouse mastocytoma P815 Somatic Cell Mol Gen 11,467-475
18. Glas, R, Ohlen, C, Hoglund, P, Karre, K. (1994) The CD8+ T cell repertoire in beta 2-microglobulin-deficient mice is biased towards reactivity against self-major histocompatibility class I J Exp Med 179,661-672[Abstract/Free Full Text]
19. Merten, S, Chen, JC, Ha, H, et al (1998) The cellular basis of cardiac allograft rejection, VIII: mechanisms underlying delayed allograft rejection in PVG C6-deficient rats Transplantation 65,1152-1158[Medline][Order article via Infotrieve]
20. Russell, PS, Chase, CM, Winn, HJ, Colvin, RB (1994) Coronary atherosclerosis in transplanted mouse hearts, II: importance of humoral immunity J Immunol 152,5135-5141[Abstract]
21. Goslings, WR, Yamada, J, Dana, MR, et al (1999) Corneal transplantation in antibody-deficient hosts Invest Ophthalmol Vis Sci 40,250-253[Abstract/Free Full Text]
22. Hall, BM, de Saxe, I, Dorsch, SE (1983) The cellular basis of allograft rejection in vivo, III: restoration of first-set rejection of heart grafts by T helper cells in irradiated rats Transplantation 36,700-705[Medline][Order article via Infotrieve]
23. Rosenberg, AS, Mizuochi, T, Sharrow, SO, Singer, A. (1987) Phenotype, specificity, and function of T cell subsets and T cell interactions involved in skin allograft rejection J Exp Med 165,1296-1315[Abstract/Free Full Text]
24. He, YG, Ross, J, Niederkorn, JY (1991) Promotion of murine orthotopic corneal allograft survival by systemic administration of anti-CD4 monoclonal antibody Invest Ophthalmol Vis Sci 32,2723-2728[Abstract/Free Full Text]
25. Yamada, J, Kurimoto, I, Streilein, JW (1999) Role of CD4⁺ T cells in immunobiology of orthotopic corneal transplants in mice Invest Ophthalmol Vis Sci 40,2614-2621[Abstract/Free Full Text]
26. Joo, C, Pepose, JC, Stuart, PM (1995) T cell mediated responses in a murine model of orthotopic corneal transplantation Invest Ophthalmol Vis Sci 36,1530-1540[Abstract/Free Full Text]
27. Ayliffe, W, Alam, Y, Bell, EB, McLeod, D, Hutchinson, IV (1992) Prolongation of rat corneal graft survival by treatment with anti-CD4 monoclonal antibody Br J Ophthalmol 76,602-606[Abstract/Free Full Text]
28. Katami, M. (1991) Corneal transplantation-immunological privileged status Eye 5,528-548
29. Goldberg, MF, Ferguson, TA, Pepose, JS (1994) Detection of cellular adhesion molecules in inflamed human corneas Ophthalmology 101,161-168[Medline][Order article via Infotrieve]
30. Griffith, TS, Brunner, T, Fletcher, SM, Green, DR, Ferguson, TA (1995) Fas ligand-induced apoptosis as a mechanism of immune privilege Science 270,1189-1192[Abstract/Free Full Text]
31. Stuart, PM, Griffith, TS, Usui, N, et al (1997) CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival J Clin Invest 99,396-402[Medline][Order article via Infotrieve]
32. Yamagami, S, Kawashima, H, Tsuru, T, et al (1997) Role of Fas-Fas ligand interactions in the immunorejection of allogeneic mouse corneal transplants Transplantation 64,1107-1111[Medline][Order article via Infotrieve]

This article has been cited by other articles:

				L. Shen, Y. Jin, G. J. Freeman, A. H. Sharpe, and M. R. Dana The Function of Donor versus Recipient Programmed Death-Ligand 1 in Corneal Allograft Survival J. Immunol., September 15, 2007; 179(6): 3672 - 3679. [Abstract] [Full Text] [PDF]

				S. Huq, Y. Liu, G. Benichou, and M. R. Dana Relevance of the Direct Pathway of Sensitization in Corneal Transplantation Is Dictated by the Graft Bed Microenvironment J. Immunol., October 1, 2004; 173(7): 4464 - 4469. [Abstract] [Full Text] [PDF]

				A Vitova, M Filipec, A Zajicova, M Krulova, and V Holan Prevention of corneal allograft rejection in a mouse model of high risk recipients Br. J. Ophthalmol., October 1, 2004; 88(10): 1338 - 1342. [Abstract] [Full Text] [PDF]

				P. Zamiri, Q. Zhang, and J. W. Streilein Vulnerability of Allogeneic Retinal Pigment Epithelium to Immune T-Cell-Mediated Damage In Vivo and In Vitro Invest. Ophthalmol. Vis. Sci., January 1, 2004; 45(1): 177 - 184. [Abstract] [Full Text] [PDF]

				J. Y. Niederkorn The immune privilege of corneal grafts J. Leukoc. Biol., August 1, 2003; 74(2): 167 - 171. [Abstract] [Full Text] [PDF]

				R. Higuchi and J. W. Streilein CD8+ T Cell-Mediated Delayed Rejection of Orthotopic Guinea Pig Cornea Grafts in Mice Deficient in CD4+ T Cells Invest. Ophthalmol. Vis. Sci., January 1, 2003; 44(1): 175 - 182. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yamada, J. Articles by Streilein, J. W. Search for Related Content PubMed PubMed Citation Articles by Yamada, J. Articles by Streilein, J. W.